between the levels of Th17 lymphocytes (CD4+IL-17+, pTh17, and npTh17) and different disease parameters in patients with RA, including those with early disease and naïve to antirheumatic drugs as well as in patients with established disease and under therapy. This evidence concerns the gene CD4 and rheumatoid arthritis.